ES2182900T3 - Extractos de cartilago de tiburon, que tienen una actividad anti-angiogenica y efecto en regresion de tumor, proceso para su produccion. - Google Patents

Extractos de cartilago de tiburon, que tienen una actividad anti-angiogenica y efecto en regresion de tumor, proceso para su produccion.

Info

Publication number
ES2182900T3
ES2182900T3 ES95916523T ES95916523T ES2182900T3 ES 2182900 T3 ES2182900 T3 ES 2182900T3 ES 95916523 T ES95916523 T ES 95916523T ES 95916523 T ES95916523 T ES 95916523T ES 2182900 T3 ES2182900 T3 ES 2182900T3
Authority
ES
Spain
Prior art keywords
activity
cartilago
extracts
superior
bolita
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95916523T
Other languages
English (en)
Inventor
Eric Dupont
Paul Brazeau
Christina Juneau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosciens Biopharma Inc
Original Assignee
Les Laboratories Aeterna Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratories Aeterna Inc filed Critical Les Laboratories Aeterna Inc
Application granted granted Critical
Publication of ES2182900T3 publication Critical patent/ES2182900T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A EXTRACTOS DE CARTILAGO DE TIBURON Y A UN METODO PARA PRODUCIRLOS, ESTOS EXTRACTOS TIENEN PROPIEDADES ANTIANGIOGENICAS (SE HA OBSERVADO IN VIVO LA REDUCCION DEL AREA DE VASOS SANGUINEOS EN TUMORES INDUCIDOS EXPERIMENTALMENTE), ACTIVIDAD REGRESIVA DEL TUMOR IN VIVO ASI COMO DEMUESTRAN UN EFECTO INHIBITORIO DIRECTO EN LAS LINEAS CELULARES DEL TUMOR. ESTE PROCESO NO NECESITA DE NINGUN PRODUCTO O SOLVENTE DESNATURALIZADOR NI EL USO DE NINGUNA ENZIMA. CONSISTE EN OBTENER UNA MEZCLA DEL CONJUNTO DEL CARTILAGO EN UNA SOLUCION ACUOSA DE PH NEUTRAL, PREFERIBLEMENTE AGUA PURA, ESTA MEZCLA ES CENTRIFUGADA GUARDANDOSE LA BOLITA Y EL SOBRENADANTE PARA UN PROCESAMIENTO POSTERIOR. LA BOLITA SE LIOFILIZA Y PRUEBA EN LAS ACTIVIDADES ANTITUMORALES Y ANTIANGIOGENICA IN VIVO E IN VITRO, CON O SIN SOBRENADANTE. EL SOBRENADANTE HA DEMOSTRADO TENER IN VIVO ACTIVIDAD ANGIOGENICA Y DE REGRESION TUMORAL. LA COMPOSICION DEL SOBRENADANTE SE HA INVESTIGADO DE DIFERENTES FORMAS. EL FRACCIONAMIENTO DE ESTE SOBRENADANTE PERMITIO LA CARACTERIZACION DE ALGUNOS DE SUS COMPONENTES ACTIVOS. LA ACTIVIDAD DIRECTA IN VIVO DE LAS FRACCIONES HA SIDO PROBADA EN LAS LINEAS CELULARES TUMORALES. ADEMAS SE ASUME QUE EL SOBRENADANTE NO FRACCIONADO TIENE LA MISMA ACTIVIDAD IN VITRO. LA LIOFILIZACION DESTRUYE SUSTANCIALMENTE LA ACTIVIDAD DE ESTAS FRACCIONES LIQUIDAS SIN QUE SE HAYA OBSERVADO ESTA DESTRUCCION EN EL EXTRACTO SOLIDO.
ES95916523T 1994-04-28 1995-04-21 Extractos de cartilago de tiburon, que tienen una actividad anti-angiogenica y efecto en regresion de tumor, proceso para su produccion. Expired - Lifetime ES2182900T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23401994A 1994-04-28 1994-04-28
US08/384,555 US5618925A (en) 1994-04-28 1995-02-03 Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof

Publications (1)

Publication Number Publication Date
ES2182900T3 true ES2182900T3 (es) 2003-03-16

Family

ID=26927471

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95916523T Expired - Lifetime ES2182900T3 (es) 1994-04-28 1995-04-21 Extractos de cartilago de tiburon, que tienen una actividad anti-angiogenica y efecto en regresion de tumor, proceso para su produccion.

Country Status (24)

Country Link
US (2) US5618925A (es)
EP (1) EP0759765B1 (es)
JP (1) JPH09512563A (es)
KR (1) KR100378787B1 (es)
CN (2) CN1147305C (es)
AT (1) ATE224198T1 (es)
BG (1) BG62954B1 (es)
BR (1) BR9507552A (es)
CA (1) CA2188793C (es)
CZ (1) CZ290520B6 (es)
DE (1) DE69528258T2 (es)
DK (1) DK0759765T3 (es)
ES (1) ES2182900T3 (es)
FI (1) FI117375B (es)
HU (1) HU220784B1 (es)
IS (1) IS1975B (es)
NO (1) NO317674B1 (es)
NZ (1) NZ284407A (es)
PL (1) PL181981B1 (es)
PT (1) PT759765E (es)
RO (1) RO114868B1 (es)
RU (1) RU2156132C2 (es)
SI (1) SI0759765T1 (es)
WO (1) WO1995032722A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025334A (en) * 1994-04-28 2000-02-15 Les Laboratoires Aeterna Inc. Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof
US6380366B1 (en) * 1994-04-28 2002-04-30 Les Laboratoires Aeterna Inc. Shark cartilage extract:process of making, methods of using and compositions thereof
US5618925A (en) * 1994-04-28 1997-04-08 Les Laboratories Aeterna Inc. Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof
US6028118A (en) * 1996-08-08 2000-02-22 Les Laboratoires Aeterna Inc. Methods of using extracts of shark cartilage
RO117590B1 (ro) * 1995-02-03 2002-05-30 Aeterna Lab Inc Compozitie pentru tratamentul unei degenerari, boli colagenice sau inflamatorii
US5843920A (en) * 1996-09-16 1998-12-01 Biocell Technology, Llc Anionic saccharides for extraction of anti-angiogenic protein from cartilage
WO1998036760A1 (en) * 1997-02-20 1998-08-27 Industrial Research Limited Angiogenesis inhibitors and activators from shark cartilage
CA2281570C (en) * 1997-03-11 2003-09-23 Les Laboratoires Aeterna Inc. Composition for treating tumors containing shark cartilage extracts and anti-neoplastic agents
CA2295519C (en) * 1997-07-11 2008-12-16 Cv Technologies Inc. A preparation derived from shark cartilage for treatment of diseases related to excessive phf or excessive intracellular calcium
US5840342A (en) * 1997-09-17 1998-11-24 Raithaus; Lawrence R. Shark liver extract for stimulating the immune system
FR2778558B1 (fr) * 1998-05-12 2001-02-16 Oreal Utilisation d'inhibiteur de metalloproteinases pour induire et/ou stimuler la croissance des cheveux ou des poils et/ou freiner leur chute
EP1096955B9 (en) 1998-07-13 2006-07-05 Board of Regents, The University of Texas System Uses of antibodies to aminophospholipids for cancer treatment
US20020009501A1 (en) * 1998-07-23 2002-01-24 Eric Dupont Preparation of cartilage extracts using organic solvents
US6168807B1 (en) 1998-07-23 2001-01-02 Les Laboratoires Aeterna Inc. Low molecular weight components of shark cartilage, processes for their preparation and therapeutic uses thereof
EP1234585A3 (en) 1998-09-04 2004-01-21 The Regents Of The University Of Michigan Methods and compositions for the prevention or treatment of cancer
CN1064690C (zh) * 1998-09-10 2001-04-18 中国人民解放军海军医学研究所 鲨鱼软骨血管生成抑制因子及其分离纯化方法
US7361643B2 (en) 2000-02-09 2008-04-22 University Of Puerto Rico Methods for inhibiting angiogenesis
CA2423331A1 (en) * 2000-12-20 2002-06-27 Industrial Research Limited Shark meat extract
AUPR222300A0 (en) * 2000-12-21 2001-01-25 Life Therapeutics Limited Electrophoresis device and method
US20030095981A1 (en) * 2001-05-30 2003-05-22 Kin-Ping Wong Compositions containing an active fraction isolated from ganoderma lucidum and methods of use
US20030087830A1 (en) * 2001-06-12 2003-05-08 Eric Dupont Low molecular weight components of cartilage, complexes of metals with amino acids, DI-peptides and analogs thereof; processes for preparation and therapeutic uses thereof
US7309501B2 (en) * 2001-06-21 2007-12-18 Mote Marine Laboratory Conditioned media to inhibit growth of tumor cells
US6908627B2 (en) * 2001-06-21 2005-06-21 Mote Marine Laboratory Conditioned media for inhibiting growth of tumor cells
US7504115B2 (en) 2002-02-15 2009-03-17 Ocean Nutrition Canada Limited Shark cartilage extracts and use thereof for immunomodulation
RU2270023C2 (ru) * 2002-02-20 2006-02-20 Какухиро Ко., Лтд. Способ экстракции и очистки протеогликана хрящевого типа (варианты)
DE60335383D1 (de) 2002-07-15 2011-01-27 Univ Texas Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
US20070010430A1 (en) * 2003-03-20 2007-01-11 Hosokawa Micron Corparation Proteoglycan isolated from cartilaginous fish and process for producing the same
US7067123B2 (en) 2003-04-29 2006-06-27 Musculoskeletal Transplant Foundation Glue for cartilage repair
US7901457B2 (en) * 2003-05-16 2011-03-08 Musculoskeletal Transplant Foundation Cartilage allograft plug
ES2223291B1 (es) * 2003-08-06 2006-03-16 Bioiberica, S.A. Nuevo uso terapeutico de condroitin sulfato.
EP2335650B1 (en) 2003-12-11 2012-10-03 Isto Technologies Inc. Particulate cartilage system
HRP20130459T1 (en) 2004-01-22 2013-06-30 University Of Miami Topical co-enzyme q10 formulations and methods of use
CN100377741C (zh) * 2004-02-23 2008-04-02 江卫世 注射用复方骨肽及其制备工艺
US20050288796A1 (en) * 2004-06-23 2005-12-29 Hani Awad Native soft tissue matrix for therapeutic applications
US20090319045A1 (en) 2004-10-12 2009-12-24 Truncale Katherine G Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
US7837740B2 (en) * 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
WO2006059236A2 (en) * 2004-11-16 2006-06-08 Aeterna Zentaris Inc. Method of using cartilage extract for increasing blood parameters
US7815926B2 (en) * 2005-07-11 2010-10-19 Musculoskeletal Transplant Foundation Implant for articular cartilage repair
JP5292533B2 (ja) 2005-08-26 2013-09-18 ジンマー・インコーポレイテッド インプラントおよび関節疾患の治療、置換および治療方法
CA2623106C (en) 2005-09-19 2013-12-24 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
DE102006060247A1 (de) * 2006-09-15 2008-03-27 Ossacur Ag Differenzierung von Stammzellen
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
US8435551B2 (en) 2007-03-06 2013-05-07 Musculoskeletal Transplant Foundation Cancellous construct with support ring for repair of osteochondral defects
EP2134297B1 (en) 2007-04-12 2017-03-08 Zimmer, Inc. Apparatus for tissue repair
WO2009060198A1 (en) 2007-11-09 2009-05-14 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
CA2749750C (en) * 2008-04-15 2014-01-28 Immanence Integrale Dermo Correction Inc. Skin care compositions and methods of use thereof
EP2323679A4 (en) 2008-07-25 2012-08-22 Univ Colorado CLIP INHIBITORS AND METHODS FOR MODULATING IMMUNE FUNCTION
WO2010083051A2 (en) * 2009-01-15 2010-07-22 ProChon Biotech, Ltd. Cartilage particle tissue mixtures optionally combined with a cancellous construct
CN101891811B (zh) * 2010-05-28 2011-11-09 暨南大学 一种鲨鱼血管生成抑制因子及其生产纯化方法和应用
CN101899104B (zh) * 2010-05-28 2012-04-18 暨南大学 一种鲨鱼软骨血管生成抑制因子小分子多肽及其生产纯化方法和应用
US9284359B2 (en) * 2011-01-19 2016-03-15 Hirosaki University Method for mass preparation of proteoglycan
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
CN104894200B (zh) * 2015-05-12 2020-10-30 浙江海洋学院 路氏双髻鲨软骨血管生成抑制因子的制备方法
KR101628982B1 (ko) 2015-11-27 2016-06-09 김준혁 항종양 및 면역 증강용 건강식품 조성물
US10786471B2 (en) 2017-02-06 2020-09-29 Massachusetts Institute Of Technology Methods and products related to glutaminase inhibitors
CN109394786A (zh) * 2018-10-26 2019-03-01 西交利物浦大学 一种抗肿瘤的药物组合物
JP7366377B2 (ja) * 2019-03-29 2023-10-23 慶應義塾 魚介類由来成分による低酸素応答制御
WO2020251412A2 (ru) * 2019-06-14 2020-12-17 Общество С Ограниченной Ответственностью "Айтупайф" (Ооо "Айтулайф") Способ получения йодированных белков с детерминированным содержанием йода
CN112986499A (zh) * 2021-02-26 2021-06-18 山西奥瑞生物材料有限公司 一种同种骨植入材料残余水量均匀度测定方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3478146A (en) * 1965-02-26 1969-11-11 Leslie L Balassa Wound-healing cartilage powder extracting process
US4042457A (en) * 1975-11-10 1977-08-16 Rush-Presbyterian-St. Luke's Medical Center Preparation of tissue invasion inhibitor and method of treatment utilizing the inhibitor
US4822607A (en) * 1976-10-29 1989-04-18 Lescarden Ltd. Anti-tumor agent and method
US4243582A (en) * 1979-04-26 1981-01-06 Monsanto Company Novel glycoproteins from bovine cartilage
US4350682A (en) * 1979-05-11 1982-09-21 Lescarden Ltd. Cartilage extraction processes and products
US4356261A (en) * 1980-04-22 1982-10-26 Rush-Presbyterian-St. Luke's Medical Center Anti-invasion factor containing cultures
US4473551A (en) * 1982-08-23 1984-09-25 Faxon Pharmaceuticals, Inc. Anti-inflammatory composition
US4486414A (en) * 1983-03-21 1984-12-04 Arizona Board Of Reagents Dolastatins A and B cell growth inhibitory substances
US4656137A (en) * 1985-09-12 1987-04-07 Lescarden Inc Method of processing animal cartilage
US4749522A (en) * 1985-10-31 1988-06-07 Angio-Medical Corporation Supercritical fluid extraction of animal derived materials
US4746729A (en) * 1986-07-30 1988-05-24 Kuettner Klaus E Cartilage-derived leukocyte elastase-inhibitor
US5075112A (en) * 1990-02-12 1991-12-24 Cartilage Technologies Inc. Method of and dosage unit for inhibiting angiogenesis or vascularization in an animal using shark cartilage
AU5596494A (en) * 1992-11-30 1994-06-22 I. William Lane Processing shark cartilage
RU2019180C1 (ru) * 1993-01-12 1994-09-15 Яков Давидович Безман Средство для лечения подкожной фибросаркомы и способ его получения
RU2019173C1 (ru) * 1993-01-12 1994-09-15 Яков Давидович Безман Способ лечения подкожной фибросаркомы
DE69403966T3 (de) * 1993-07-19 2008-04-17 Angiotech Pharmaceuticals, Inc., Vancouver Anti-angiogene mittel und verfahren zu deren verwendung
US5618925A (en) * 1994-04-28 1997-04-08 Les Laboratories Aeterna Inc. Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof

Also Published As

Publication number Publication date
AU719118B2 (en) 2000-05-04
US5985839A (en) 1999-11-16
PT759765E (pt) 2003-02-28
WO1995032722A1 (en) 1995-12-07
SI0759765T1 (en) 2003-02-28
EP0759765A1 (en) 1997-03-05
DK0759765T3 (da) 2003-01-27
AU2300195A (en) 1995-12-21
CA2188793A1 (en) 1995-12-07
DE69528258D1 (de) 2002-10-24
BG100941A (en) 1997-07-31
HU220784B1 (hu) 2002-05-28
CN1541656A (zh) 2004-11-03
CA2188793C (en) 2001-01-16
KR970702729A (ko) 1997-06-10
PL181981B1 (en) 2001-10-31
EP0759765B1 (en) 2002-09-18
BG62954B1 (bg) 2000-12-29
NZ284407A (en) 1998-04-27
FI964327A7 (fi) 1996-12-20
FI964327A0 (fi) 1996-10-28
RU2156132C2 (ru) 2000-09-20
US5618925A (en) 1997-04-08
NO964547D0 (no) 1996-10-25
IS4379A (is) 1996-10-25
HU9602975D0 (en) 1997-01-28
CZ314196A3 (en) 1997-04-16
KR100378787B1 (ko) 2003-06-19
PL317076A1 (en) 1997-03-03
JPH09512563A (ja) 1997-12-16
FI117375B (fi) 2006-09-29
ATE224198T1 (de) 2002-10-15
CZ290520B6 (cs) 2002-08-14
HUT76554A (en) 1997-09-29
CN1147305C (zh) 2004-04-28
NO964547L (no) 1996-12-30
RO114868B1 (ro) 1999-08-30
IS1975B (is) 2005-01-14
BR9507552A (pt) 1997-08-05
DE69528258T2 (de) 2003-04-17
CN1153477A (zh) 1997-07-02
NO317674B1 (no) 2004-11-29

Similar Documents

Publication Publication Date Title
BR9507552A (pt) Extrato de cartilagem de tubarão tendo uma atividade angiogênica e um efeito sobre regressão de tumor e processo para a sua preparação
ES2190475T3 (es) Extractos de cartilago de tiburon.
CL2004000675A1 (es) Uso de una combinacion de androgeno de origen biogenico o sintetico y un estrogeno de origen biogenico o sintetico para preparar un medicamento util en el tratamiento del hipogonadismo y enfermedades hipofisis o glandula pituitaria en hombres, para e
DK545584A (da) Enzym-resistente immonumodulatoriske peptider
ES2061632T3 (es) Kluyveromyces como celula hospedante.
ES2097783T3 (es) Nanomatrices proteicas y procedimiento de produccion.
ES489204A1 (es) Elemento destinado a implantarse en tejido corporal, parti- cularmente tejido oseo
BR9908165A (pt) Processos de prevenção de um citotóxico de proteìna beta amilóide em células, de tratamento de uma fibrilogênica em um sujeito humano, de diminuição da oxidação em uma amostra biológica e de tratamento de doenças ou outros quadros em que radicais livres e/ou tensão oxidativa desempenham um papel, e, uso de ácido indol-3-propiÈnico ou um seu sal ou éster.
ES2170274T3 (es) Metodo y preparaciones para estabilizar materiales biologicos por metodos de secado sin congelamiento.
ES2054842T3 (es) Analogo del factor viii, procedimiento de preparacion y composicion farmaceutica que lo contiene.
AR022578A1 (es) Peptidos artificiales que tienen actividad superficial y el uso de los mismos en la preparacion de un tensioactivo artificial
ES2049695T3 (es) Procedimiento para la obtencion de cera de manzana, cera de manzana obtenible mediante este procedimiento y productos cosmeticos con contenido en cera de manzana.
ES2194513T3 (es) Composiciones para el tratamiento y prevencion de enfermedades neurologicas y patopsicologicas.
ES2156107T3 (es) Un fgf-4 no glicosilado y composiciones que lo contienen.
ES2123714T3 (es) Aislamiento y estructura de las esponjistatinas 5,7,8 y 9 y su empleo como agentes antitumorales.
Beams et al. Light and electron microscope studies on the light organ of the firefly (Photinus pyralis)
MX2020008120A (es) Metodos y composiciones para inhibir las actividades biologicas de adam9.
ES2147556T3 (es) Proteina relativa al hueso, del tipo carboxipeptidasa y procedimiento para su produccion.
WO2024238955A3 (en) Relaxin-2 fusion protein analogs and methods of using same
ES2185698T3 (es) Composicion de tratamiento anti-acne de la piel.
GT200400241A (es) Prevencion y tratamiento de enfermedades cardiacas hipertensivas mediante el uso de los estrogenos selectivos8b-vinil-estra-1,3,5,(10)-trien-3,17b-diol y 17b-fluor-9a-vinil-estra-1,3,6,(10)-trien-3, 16a-diol
FR3134010B1 (fr) Utilisation cosmétique, nutraceutique et/ou dermatologique d’une souche de Lactobacillus crispatus et/ou d’une composition la comprenant
WO2018137748A3 (en) Antiviral, antifibrotic and anticancer activities of royal-jelly proteins
DK179488A (da) Desinfektionspraeparat
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.